The UF Health Cancer Center will be well-represented at the American Society of Hematology (ASH) 65th Annual Meeting & Exposition in San Diego from Dec. 8-12.
The ASH Annual Meeting is the most comprehensive hematology event of the year. The meeting will provide an invaluable educational experience and overview of the latest scientific highlights in hematology. ASH is a great opportunity for hematology/oncology researchers to engage with colleagues and network with more than 25,000 hematology professionals from every subspecialty.
The full conference program is available here.
UF Health Cancer Center members appear in bold. UF Health Cancer Center trainees are underlined.
Scientific Workshop
Friday, Dec. 8
Epigenetic and Chromatin Mechanisms Implicated in Therapy Resistance | 2:01-2:45 p.m.
NSD2 and Glucocorticoid Resistance in Acute Lymphoblastic Leukemia
Presenter: Jonathan D. Licht, M.D.
Oral Presentations
Saturday, Dec. 9
121 The Methylome Atlas of Acute Leukemia Enables Novel Clinical Diagnostic Tool for AML
9:30 a.m.
Presenter: Francisco Marchi
Authors include: Marieke Landwehr, Fernando Sckaff, Jatinder Lamba, Ph.D.
249 Real-World Implementation of Sickle Cell Transition Programs As Part of a State Quality Improvement Network
2:30 p.m.
Authors include: Debbie Ringdahl, APRN
386 Intensification of Therapy and Pharmacogenetic Personalization Mitigate Racial Disparities in Pediatric Acute Myeloid Leukemia Outcomes
4:15 p.m.
Authors include: Jatinder Lamba, Ph.D., Richard J. Marrero, Pharm.D.
Sunday, Dec. 10
398 B4galt1 Regulates the WNT-β-Catenin Axis to Control Hematopoietic Stem and Progenitor Cells (HSPCs) Fitness
9:45 a.m.
Authors include: Lindsey Conroy, Ph.D., Ramon Sun, Ph.D.
465 Discovery and Development of CD70 As a Cellular Therapy Target in High Risk Multiple Myeloma
10 a.m.
Authors include: Daphne Dupere-Richer, Ph.D.
517 Risk-Adjusted Therapies Yield Equivalent Outcomes for Adolescents and Young Adults (AYAs) Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) on Children’s Oncology Group (COG) Studies AALL0434 and AALL1231
12 p.m.
Authors include: Zhiguo (Bruce) Chen, M.S.
672 Longitudinal Differences By Treatment Arm in Health-Related Quality of Life Among High Risk Pediatric Hodgkin’s Lymphoma Patients Treated on the Children’s Oncology Group Ahod 1331 Study
5:45 p.m.
Authors include: Qinglin Pei, Ph.D.
Monday, Dec. 11
835 A DNA Methylation Signature Predicts Clinical Outcome in Pediatric AML Patients
2:45 p.m.
Presenter: Francisco Marchi
Authors include: Jatinder Lamba, Ph.D., Marieke Landwehr, Fernando Sckaff
798 Grndad and Disease Modifying Therapy (DMT): Shifts in Dmt Are Seen at the Adolescent/Young Adult Transition in Sickle Cell Disease in a Multi-Site Prospective Registry
4 p.m.
Authors include: Molly Mandernach, M.D.
973 Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated
4:30 p.m.
Authors include: John R. Wingard, M.D.
961 Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL): Children’s Oncology Group AALL1131
4:30 p.m.
Authors include: Zhiguo (Bruce) Chen, M.S.
824 Patients with Down Syndrome and High-Risk B-Acute Lymphoblastic Leukemia Demonstrate Improved Outcomes on a Modified Chemotherapy Regimen: A Report from Children’s Oncology Group Study AALL1131
3 p.m.
Authors include: Zhiguo (Bruce) Chen, M.S.
Poster Presentations
Saturday, Dec. 9
5:30-7:30 p.m.
1558 Leveraging Custom CRISPR/Cas9 Screens to Identify AraC-Daunorubicin-Etoposide (ADE), Gemtuzumab Ozogamicin (GO), and Bortezomib Response Modulators Association with Clinical Outcomes in Pediatric AML
Presenter: Nam Nguyen, Pharm.D.
Authors include: Phani Krishna Parcha, Ph.D., Abderrahmane Tagmount, Ph.D., Bailey Gregory
1412 CRISPR/Cas9 Screen Identifies CPX-351 and 7+3 Regimens Response Modulators with Distinct Sensitive and Resistant Profiles
Presenter: Nam Nguyen, Pharm.D.
Authors include: Phani Krishna Parcha, Ph.D., Abderrahmane Tagmount, Ph.D., Bailey Gregory, Christopher Vulpe, M.D., Ph.D., and Jatinder K. Lamba, Ph.D.
1699 Performance of Positron Emission Tomography at Diagnosis and Response Assessment in Low and Intermediate-Risk Nodular Lymphocyte Predominant Hodgkin Lymphoma
Authors include: Qinglin Pei, Ph.D., Yue Wu
1144 Engagement with Incharge App – a Mobile Health Intervention to Improve Adherence to Hydroxyurea Among Individuals with Sickle Cell Disease
Authors include: Richard Lottenberg, M.D.
1223 A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
Authors include: John Fort, M.D.
2392 Distance to Care Predicts Clinical Trial Enrollment on COG ALL Clinical Trials: A Report from the Children’s Oncology Group
Authors include: Zhiguo (Bruce) Chen, M.S.
Sunday, Dec. 10
6-8 p.m.
2923 Relapse-Enriched Gene Expression Signature of Prognostic Relevance in Pediatric Acute Myeloid Leukemia
Presenter: Satyavardhan Rao Nittu, Pharm.D.
Authors include: Francisco Marchi, Nam Nguyen, Pharm.D., Vivek M. Shastri, Ph.D., Jatinder K. Lamba, Ph.D.
2954 Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients
Presenter: Richard J. Marrero, Pharm.D.
Authors include: Vivek M. Shastri, Ph.D., Jatinder Lamba, Ph.D.
2967 GWAS Identifies Variants Associated with Minimal Residual Disease after Induction I in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia
Presenter: Richard J. Marrero, Pharm.D.
Authors include: Jatinder Lamba, Ph.D.
2926 Relapse-Enriched Gene Expression Signature of Prognostic Relevance in Pediatric Acute Myeloid Leukemia
Presenter: Satyavardhan Rao Nittu, Pharm.D.
Authors include: Francisco Marchi, Nam Nguyen, Pharm.D., Vivek M. Shastri, Ph.D., Jatinder Lamba, Ph.D.
3596 Gut Microbiome Faecalibacterium Abundance in Patients with Plasma Cell Disorders Undergoing Autologous Hematopoietic Stem Cell Transplant Is Associated with Progression Free Survival
Presenter: Erin A. Dean, M.D.
Authors include: Arkaprava Roy, Ph.D., Rick Y. Lin, M.D., Raad Z. Gharaibeh, Ph.D., Derek M. Li, Josee Gauthier, Christian Jobin, Ph.D., Zeina A. Al-Mansour, M.D., and John R. Wingard, M.D.
2857 Survival Outcomes of Acute Megakaryoblastic Leukemia in the United States: A 10-Year SEER-Based Study
Presenter: Kriti Gera, M.D.
Authors include: Daniela Martir, M.D., Doga Kahramangil, Mansi Dalal, M.D., and Bently Doonan, M.D., M.S.
3084 AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Authors include: Qinglin Pei, Ph.D., Yue Wu, Raymond Mailhot, M.D.
2771 Activating NSD2 Mutations Drive Oncogenic Reprogramming By Disturbing Epigenetic Landscape in Mantle Cell Lymphoma
Presenter: Jianping Li, M.D.
Authors include: Alberto Riva, Ph.D., Heidi Casellas Román, Daphne Dupere-Richer, Ph.D., Monica Clerio, Melanie L. Trejo, Michael Menes, Anthony Joseph Lamberto, Amin Sobh, Ph.D., Charlotte Leonie Kaestner, Ph.D., Richard Lynn Bennett, Ph.D., Iñaki I. Martin Subero, Ph.D. and Jonathan D. Licht, M.D.
3516 Incidence and Outcomes of Cytomegalovirus Reactivation after Chimeric Antigen Receptor T Cell Therapy
Presenter: Rick Y. Lin, M.D.
2976 Next-Generation Sequencing (NGS) for Residual Disease (MRD) Monitoring in T-Lymphoblastic Leukemia (T-ALL)
Authors include: Zhiguo (Bruce) Chen, M.S.
Monday, Dec. 11
6-8 p.m.
4145 C17ORF58 Is Upregulated in Peripheral T-Cell Lymphomas and Encodes a Protein Critical for Survival of PTCL Cells
Presenter: Julian Tobon, B.S.
Authors include: Pawel Nowialis, Ph.D., Katarina Lopusna, Ph.D., Duo Chen, M.S., Arshee Badar, M.D., Reem Abdelghany, Emma Noel, Jacob Fingeret, Gene Pozas, Jana Opavska, M.S., and Rene Opavsky, Ph.D.
4584 Compound Loss of Dnmt3a and Kmt2c in Myeloid Malignancies
Presenter: Prabhjot Kaur, Ph.D.
Authors include: Cassandra Berntsen, James Leonard, Daniil Shabashvili, Qingchen Yuan, MBBS, Bowen Yan, Ph.D., Richard Lynn Bennett, Ph.D., Alberto Riva, Ph.D., Jonathan D. Licht, M.D. and Olga A. Guryanova, M.D., Ph.D.
4314 ACS10- Cytarabine Pharmacogenomics Score Impacts Survival in Pediatric AML Patients Treated on AAML1031 Trial and Associates with Outcome Differences in Black AML Patients
Presenter: Richard J. Marrero, Pharm.D.
Authors include: Vivek M. Shastri, Ph.D., Jatinder Lamba, Ph.D.
4154 Targeting BCL-XL with a Novel VHL-Based BCL-XL Degrader DT-2216 in Pre-Clinical JAK2-Mutant AML Post-MPN Models
Authors include: Guangrong Zheng, Ph.D.
4195 Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader
Authors include: Peiyi Zhang, Guangrong Zheng, Ph.D.
4383 Identifying Tumor-Specific Immune Response and Biomarkers of High-Risk Hodgkin Lymphoma Patients Treated with and without Brentuximab on Children’s Oncology Group Trial AHOD1331
Authors include: Qinglin Pei, Ph.D.
